Abstract Number: 299 • 2019 ACR/ARP Annual Meeting
Definition of New Ultrasound Enthesophytes Score: Application in a Consecutive Series of IBD Patients
Background/Purpose: Recent studies have developed criteria for US definition of entheseal abnormalities (1), however no actual scores are available to determine the extension and severity…Abstract Number: 300 • 2019 ACR/ARP Annual Meeting
Proliferative Globular Synovitis, an Ultrasound Pattern Associated with Seropositive Rheumatoid Arthritis
Background/Purpose: Rheumatoid Arthritis (RA) has a synovial ultrasound (US) pattern, while soft tissue involvement is more frequently found in Psoriatic Arthritis (PsA). No previous studies…Abstract Number: 301 • 2019 ACR/ARP Annual Meeting
PANLAR Ultrasound Study Group Recommendations for the Use of Imaging in the Management of Patients with Gout
Background/Purpose: Gout is a metabolic disease caused by deposition of monosodium urate (MSU) monohydrate crystals in different tissues. Imaging may be useful to evaluate the…Abstract Number: 302 • 2019 ACR/ARP Annual Meeting
Clinical Impact of a Rheumatology Musculoskeletal Ultrasound Clinic at a U.S. Academic Center
Background/Purpose: Routine use of musculoskeletal ultrasound (MSK-US) to aid in clinical decision-making for rheumatology patients is less common in the United States than in Europe,…Abstract Number: 303 • 2019 ACR/ARP Annual Meeting
Utility of Power Doppler Ultrasound–Detected Synovitis for the Prediction of Flare in Psoriatic Arthritis Patients in Clinical Remission
Background/Purpose: Power Doppler ultrasound (PDUS) has been shown to detect subclinical synovitis in psoriatic arthritis (PsA). The aim of this study was to evaluate PDUS…Abstract Number: 304 • 2019 ACR/ARP Annual Meeting
The ACR’s Rheumatology Informatics System for Effectiveness (RISE) Demonstrates Improvements in Many Measures of Quality of Care Between 2015 and 2017
Background/Purpose: The ACR’s Rheumatology Informatics System for Effectiveness (RISE) is an EHR‐enabled registry that represents over 36% of the U.S. clinical rheumatology workforce and calculates…Abstract Number: 305 • 2019 ACR/ARP Annual Meeting
Naming Is Everything! the Cost of Inappropriate “Lupus Panel” Testing
Background/Purpose: Greater emphasis has been placed on cost saving measures due to ballooning healthcare cost in the U.S. ACGME now evaluates trainee ability to practice…Abstract Number: 306 • 2019 ACR/ARP Annual Meeting
Infrequent Screening but High Prevalence of Antinuclear Antibodies in Patients with Neuropsychiatric Disorders
Background/Purpose: The American College of Rheumatology (ACR) established case definitions of 19 specific neuropsychiatric syndromes seen in patients with systemic lupus erythematosus (SLE) (1). Therefore,…Abstract Number: 307 • 2019 ACR/ARP Annual Meeting
ANA-lysis: Utility of Repeated Antinuclear Antibody Testing in a Single Center
Background/Purpose: Reducing unnecessary laboratory investigations is a health economic priority. Anti-nuclear antibody (ANA) testing is performed as part of the diagnostic work up for autoimmune…Abstract Number: 308 • 2019 ACR/ARP Annual Meeting
Quality Control of Antinuclear Antibody Detection by Indirect Immunofluorescence and Flow Cytometry-based Recombinant Antigen Assays
Background/Purpose: Indirect immunofluorescence (IF) is the recommended initial test for detection of antinuclear antibodies (ANA) by the American College of Rheumatology (Ann Rheum. Dis 69:1420-2),…Abstract Number: 309 • 2019 ACR/ARP Annual Meeting
Increasing Capacity and Reducing Costs of Rituximab Administration
Background/Purpose: Rituximab (RTX) is associated with a large cost burden on the healthcare system and treatment delays that often exceed one month because the long…Abstract Number: 310 • 2019 ACR/ARP Annual Meeting
Efficacy, Immunogenicity and Cost Analysis of a Systematic Switch from Originator Infliximab to Biossimilar CT-P13 of All Patients with Inflamatory Arthritis from a Single Center
Background/Purpose: Biotechnological drugs are a fundamental resource for the treatment (Tx) of rheumatic patients (Pts). Biosimilar drugs are intended to be as effective as the…Abstract Number: 311 • 2019 ACR/ARP Annual Meeting
Documenting Bone Health for Veterans with Rheumatoid Arthritis in an Outpatient Academic Clinic: A Multiphase Quality Improvement Project
Background/Purpose: Rheumatoid Arthritis (RA) is associated with an increased risk of osteopenia and osteoporosis, which may result in fragility fractures and significant cost and morbidity. …Abstract Number: 312 • 2019 ACR/ARP Annual Meeting
Timely Glucocorticoid Tapering in Vasculitis: A Need for Improved Knowledge Translation to Limit Toxicity
Background/Purpose: High dose glucocorticoids (GC) are part of the initial treatment of ANCA-associated (AAV) and large vessel vasculitides (LVV). Prompt subsequent tapering limits toxicity. Adherence…Abstract Number: 313 • 2019 ACR/ARP Annual Meeting
Screening and Treating Hyperlipidemia in Patient’s on Tofacitinib, Tocilizumab, Sarilumab, and Baricitinib
Background/Purpose: Background/Purpose: Tofacitinib and baricitinib (JAK inhibitors) are agents used for rheumatoid arthritis (RA), seronegative spondyloarthropathy (SpA), and juvenile idiopathic arthritis (JIA). Tocilizumab and sarilumab…
ACR Meeting Abstracts